Issuances | Health Technology Assessment Division

[Department Circular No. 2022 – 0560] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)

Posted on October 28, 2022

View Post

[Department Personnel Order No. 2022 – 3725] Appointment of the Health Technology Assessment Council Core and Subcommittees

Posted on October 20, 2022

[Department Circular No. 2022 – 0537] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Insulin Glargine and Non inclusion of Insulin Detemir for Patients with Type 1 or Type 2 Diabetes Mellitus in the Philippine National Formulary (PNF)

Posted on October 14, 2022

View Post

HTAC Preliminary Recommendation on Abiraterone Acetate (250mg Tablet) and Enzalutamide (40mg Soft Gel Capsule)

Posted on October 4, 2022

Link to evidence summary Publication date: 04 October 2022 (Stakeholders may submit appeals to hta@doh.gov.ph until 18 October 2022 using the prescribe form found here: Topic Nomination ) Document Preview:

[Department Circular No. 2022 – 0291-A] Amendment to the Department Circular 2022-0291 “Health Technology Assessment Council (HTAC) Recommendation to include Potassium Citrate 15 mEq Extended Release (ER) Tablet in the Philippine National Formulary”

Posted on September 27, 2022

Link to Department Circular No. 2022 0 0291